Munich-based biotechnology company Ethris has announced encouraging topline data from a phase 1 clinical trial evaluating its lead messenger RNA (mRNA) candidate, ETH47. The therapy is intended for ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

Throughout her career, One2Treat’s Émilie Barré has focused on developing both the analytical and leadership aspects ...

Manas AI secures funding led by General Catalyst to scale AI-driven drug discovery, tackling cancer and rare diseases.

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Arctic therapeutics raises funding from EIC Fund, Kaldbakur, and Sanos Group to advance its dementia treatment, AT-001, and acne drug, AT-004. The company aims to transform the treatment landscape for ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...